“Xeltis’ technology is radically novel, it is addressing essential unmet vascular and valve clinical needs and it is showing promising results in trials that granted sustained support from current investors,” said Clemens van Blitterswijk, acting Chairman of Xeltis’ Board. Blitterswijk a Dutch scientist and internationally recognised pioneer in tissue regeneration. He’s also a partner at Dutch VC LSP, which led the Series D round.

“We are very excited about the ongoing support of Xeltis existing investors, following the expansion of our strategy into vascular applications,” said CEO Eliane Schutte. “We are leveraging the positive results from ongoing clinical and pre-clinical trial programmes to bring the development of natural cardiovascular restoration to the next phase.”

Xeltis institutional investors include VCs LSP, Kurma Partners, VI Partners, and Ysios.